Pulmonx Corp Files 8-K on Financial Condition
Ticker: LUNG · Form: 8-K · Filed: Jul 31, 2024 · CIK: 1127537
| Field | Detail |
|---|---|
| Company | Pulmonx Corp (LUNG) |
| Form Type | 8-K |
| Filed Date | Jul 31, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, operations-update
TL;DR
Pulmonx filed an 8-K on 7/31 for financial updates.
AI Summary
Pulmonx Corporation filed an 8-K on July 31, 2024, to report on its Results of Operations and Financial Condition. The filing does not contain specific financial figures or operational details in the provided text, but it serves as a notification of these updates.
Why It Matters
This 8-K filing indicates that Pulmonx Corporation is providing updates regarding its financial performance and operational status to the SEC.
Risk Assessment
Risk Level: low — This filing is a standard procedural update and does not contain information that inherently increases risk.
Key Players & Entities
- Pulmonx Corporation (company) — Registrant
- July 31, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 700 Chesapeake Drive Redwood City, CA 94063 (address) — Principal Executive Offices
FAQ
What specific financial results or conditions are being reported by Pulmonx Corporation in this 8-K filing?
The provided text of the 8-K filing does not specify the details of the financial results or conditions being reported, only that the filing pertains to 'Results of Operations and Financial Condition'.
What is the significance of filing an 8-K for 'Results of Operations and Financial Condition'?
Filing an 8-K for 'Results of Operations and Financial Condition' is a requirement for publicly traded companies to promptly disclose material information about their financial performance and status to the public.
When was this 8-K filing submitted by Pulmonx Corporation?
The 8-K filing was submitted on July 31, 2024.
What is the principal business address of Pulmonx Corporation?
The principal executive offices of Pulmonx Corporation are located at 700 Chesapeake Drive, Redwood City, CA 94063.
Under which section of the Securities Exchange Act of 1934 is this 8-K filed?
This 8-K filing is made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 517 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-07-31 16:10:04
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value LUNG The Nasdaq Stock Market
Filing Documents
- lung-20240731.htm (8-K) — 28KB
- lung2q24earningsrelease073.htm (EX-99.1) — 142KB
- pulmonxlogo.jpg (GRAPHIC) — 8KB
- 0001127537-24-000073.txt ( ) — 313KB
- lung-20240731.xsd (EX-101.SCH) — 2KB
- lung-20240731_lab.xml (EX-101.LAB) — 21KB
- lung-20240731_pre.xml (EX-101.PRE) — 12KB
- lung-20240731_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On July 31, 2024, Pulmonx Corporation (the "Company") issued a press release announcing its financial results for the second fiscal quarter ended June 30, 2024. A copy of the Company's press release dated July 31, 2024, titled "Pulmonx Reports Second Quarter 2024 Financial Results" is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit hereto) is being furnished under "Item 2.02 Results of Operations and Financial Condition" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release dated July 31 , 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Pulmonx Corporation Dated: July 31, 2024 By: /s/ Mehul Joshi Mehul Joshi Chief Financial Officer